Abstract:In effort s to achieve minimal systemic toxicity and high tumor delivery efficiencies in cancer therapy, various nanomedicine formulations having stealth polymer coatings have been developed for minimizing immune cell uptake and off-target macrophage phagocyte system (MPS) organ accumulation. Despite an initial reduction in immune cell uptake, stealth nanoparticles still initiate an antibody immune response. This response acts on subsequent administrations in treatment regimens resulting in accelerated blood clearance of particles into MPS organs, particularly the liver, where they are retained for prolonged periods. Consequently, doses after the first administration in treatment regimens have diminished tumor accumulation and increased MPS toxicity. Here, we present a strategy reducing antibody responses to each dose in a treatment regimen by alternating between polyethylene-glycol and polymethyloxazoline polymers as the nanoparticle coating between administrations. In a weekly dosing regimen, we find that the first dose of particles having either coating display similar favorable pharmacokinetics and biodistributions, thus allowing the polymers to be used interchangeably. However, when maintaining the same coating in subsequent administrations, we find that particles are in circulation at the height of the antibody immune response resulting in 50-60% decreases of circulation half-lives and tumor accumulation along with 50% increases in liver accumulation. By alternating the polymers used in the nanoparticle coating between administrations, we find each dose maintains favorable in vivo behaviors at the height of the antibody immune response to the previous administration. Furthermore, our strategy increases the clearance of particles uptaken by macrophages and hepatocytes, resulting in marked decreases in hepatotoxicity. Statement of significance While nanoparticles with coatings consisting of stealth polymers can minimize immune cell uptake, they still initiate antibody immune responses leading to rapid blood clearance and MPS sequestration of subsequent administrations within a treatment regimen. We demonstrate that by alternating PEG and PMOZ polymer coatings between weekly administrations, the antibody immune response acting on each administration is minimal, and the favorable in vivo behaviors observed with the first administration is maintained in subsequent administrations. In this case, greater tumor accumulation is achieved while curtailing excessive MPS organ accumulation and toxicity throughout a nanomedicine treatment. We envision our strategy will benefit clinical trials where frequent administrations of therapeutics are required or in sequential deliveries of prognostic and therapeutic agents. (c) 2021 Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Stealth and pseudo-stealth nanocarriers

Stealth Coating of Nanoparticles in Drug-Delivery Systems

The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting

Bioinert, Stealth or Interactive: How Surface Chemistry of Nanocarriers Determines Their Fate In Vivo

Stealth Nanocarriers in Cancer Therapy: a Comprehensive Review of Design, Functionality, and Clinical Applications

Rational Design of Cancer Nanomedicine for Simultaneous Stealth Surface and Enhanced Cellular Uptake.

Bioinspired "Active" Stealth Magneto-Nanomicelles for Theranostics Combining Efficient MRI and Enhanced Drug Delivery

Polytonic Drug Release via Multi-Hierarchical Microstructures Enabled by Nano-Metamaterials

Nanomedicine approaches and strategies for gum-based stealth nanocarriers

Alkoxy cyanoacrylate-based nanoparticles with stealth and brain-targeting properties

Lubricant-entrenched Slippery Surface-based Nanocarriers to Avoid Macrophage Uptake and Improve Drug Utilization

Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles

Exploring the Impact of Nanoparticle Stealth Coatings in Cancer Models: From PEGylation to Cell Membrane-Coating Nanotechnology

Body Distribution and in Situ Evading of Phagocytic Uptake by Macrophages of Long-Circulating Poly (ethylene Glycol) Cyanoacrylate-Co-n-hexadecyl Cyanoacrylate Nanoparticles.

Alternating Stealth Polymer Coatings Between Administrations Minimizes Toxic and Antibody Immune Responses Towards Nanomedicine Treatment Regimens.

Zwitterionic Drug Nanocarriers: A Biomimetic Strategy for Drug Delivery

Covalently PEGylated Carbon Nanotubes with Stealth Character in Vivo.

Advances of biological-camouflaged nanoparticles delivery system

Design of fluorinated stealth poly(ε-caprolactone) nanocarriers

The development of nanocarriers for natural products

Nanoparticle biointerfacing by platelet membrane cloaking